The Current and Potential Role of IL-12/23 and IL-23 Inhibition in Data-Driven Management of IBD

Monday, December 5, 2022

1:00 PM – 2:00 PM

Location: Northern Hemisphere C

Chair(s)

Millie D. Long, MD, MPH, FACG

Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Speaker(s)

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Professor of Medicine; Executive Vice Chair of Internal Medicine; Associate Chief Medical Officer of UC Health and Cincinnati Children's Hospital
University of Cincinnati
Cincinnati, Ohio
Corey A. Siegel, MD, MS

Section Chief of Gastroenterology and Hepatology
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

1:00 PM Introduction and Pre-Activity Survey
Millie D. Long, MD, MPH, FACG

1:05 PM Efficacy and Safety of Current and Emerging Interleukin Inhibitors for IBD
Corey Siegel, MD

1:25 PM Data-Driven Treatment of IBD in the Era of Emerging IL-23 Agents
Anita Afzali, MD, MPH, FACG

1:40 PM Case Discussion—Applying what we learned
Millie D. Long, MD, MPH, FACG

1:50 PM Panel Discussion Q&A and Post-Activity Survey
Millie D. Long, MD, MPH, FACG; Anita Afzali, MD, MPH, FACG; Corey Siegel, MD

Learning Objectives:

Describe the pathophysiologic rationale for the development of IL-12/23 and IL-23 inhibitors for IBD
Assess the safety and efficacy data associated with current and emerging IL-12/23 and IL-23 inhibitors
Evaluate and utilize data-driven treatment algorithms for IBD management